Results 111 to 120 of about 211,755 (262)

Single‐Cell Profiling Reveals Distinct Immune Hallmarks in Untreated Primary Colorectal and Liver Metastasis Cancers

Chronic Diseases and Translational Medicine, EarlyView.
Features the major cell type compositions among colon and liver metastasis. (A) The study design for single‐cell data analysis. (B) The annotated major cell types. Each type was labeled with a special color. (C) Dot plot of canonical marker genes for major cell types. (D) Bar plot of the percentage for each cell type in individuals. (E) Bar plot of the
Zhixun Zhao, Haipeng Chen, Xu Guan, Zheng Jiang, Zheng Liu, Ming Yang, Hengchang Liu, Tianli Chen, Shuangmei Zou, Yibo Gao, Xishan Wang   +10 more
wiley   +1 more source

De Novo Design of Multivalent α/β‐Peptides Mimicking Transcription Factors Targeting the CBP KIX Domain

Chemistry – A European Journal, EarlyView.
A modular, de novo α/β‐peptide design strategy allows fine‐tuning of ligand properties, resulting in multivalent ligands that simultaneously target separate binding sites on the protein surface. ABSTRACT Protein‐protein interactions that regulate gene expression in the nucleus are increasingly recognized as potential therapeutic targets but present ...
Márk V. Tresztián, Vencel L. Petrovicz, Edit Wéber, Tamás A. Martinek, Zsófia Hegedüs   +4 more
wiley   +1 more source

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real‐world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs).
Natalie Levy, Paige Sheridan, Ulka Campbell, David Lenis, Inish O'Doherty, Adina Estrin, Nileesa Gautam, Monica Iyer, Sarah McDonald, Andrew Belli, Gillis Carrigan, K. Arnold Chan, James Chen, Victoria Chia, Neil Dhopeshwarkar, Joy Eckert, Laura Fernandes, Joel Greshock, Rachele Hendricks‐Sturrup, Jenny Huang, XiaoLong Jiao, Sajan Khosla, Orsolya Lunacsek, Lynn McRoy, Yanina Natanzon, Osayi Ovbiosa, Nelson Pace, Simone Pinheiro, Megan Rees, Jennifer Rider, Mothaffar Fahed Rimawi, Travis Robinson, Carla Rodriguez‐Watson, Chithra Sangli, Khaled Sarsour, Sebastian Schneeweiss, Mark Shapiro, Mark Stewart, Aliki Taylor, C. K. Wang, Shirley Wang, Yiduo Zhang, Ann Madsen   +42 more
wiley   +1 more source

Novel treatment strategies in acute myeloid leukemia. [PDF]

Blood Res
Simkhada S, Joshi U, Dhakal P.
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Whole genome sequencing in acute myeloid leukemia. [PDF]

Haematologica
Haferlach T.
europepmc   +1 more source

Genetic Determinants of Treatment‐Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia

Clinical Pharmacology &Therapeutics, EarlyView.
Osteonecrosis and fractures are serious corticosteroid‐induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustness of both newly identified and previously ...
Rachid Abaji, Vincent Gagné, Émilie Espagne, Nathalie Alos, Veronica Del Vecchio, Lamia Ait Said, Albert Shalmiev, Claire Fuchs, Caroline Laverdière, Jean‐Marie Leclerc, Stephen E. Sallan, Lewis B. Silverman, Daniel Sinnett, Thai Hoa Tran, Maja Krajinovic   +14 more
wiley   +1 more source

Mutational profiling in acute myeloid leukemia. [PDF]

Haematologica
DiNardo CD.
europepmc   +1 more source

Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Measurable residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) is well established in bone marrow (BM) samples for acute myeloid leukemia (AML), but its use in peripheral blood (PB) remains less developed. We adapted a semi‐automated and well validated MFC‐MRD assay, originally developed for BM, to PB aiming to evaluate ...
Jonas Schadt, Malte von Bonin, Uta Oelschlägel, Christoph Röllig, Christian Thiede, Leo Ruhnke, Martin Bornhäuser, Sebastian Brenner, Maximilian Alexander Röhnert   +8 more
wiley   +1 more source

[Retracted] SHIP1 is targeted by miR‑155 in acute myeloid leukemia. [PDF]

Oncol Rep
Xue H, Hua LM, Guo M, Luo JM.
europepmc   +1 more source